Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Expression of oncogenic Kras G12D initiates lung adenomas in a mitogen-activated protein kinase (MAPK) signal-dependent manner from only a subset of cell types in the adult mouse lung. Amplification of MAPK signaling is associated with progression to malignant adenocarcinomas, but whether this is a cause or a consequence of disease progression is not known. To better understand the effects of MAPK signaling downstream of Kras G12D expression, we capitalized on the ability of Braf inhibition to selectively amplify MAPK pathway signaling in Kras G12D -expressing epithelial cells. MAPK signal amplification indeed promoted the rapid progression of established adenomas to malignant adenocarcinomas. However, we observed, surprisingly, a greater number of overall tumor-initiating events after MAPK signal amplification, due to induced proliferation of cell types that are normally refractory to Kras G12D -induced transformation. Thus, MAPK signaling in the lung is thresholded not only during malignant progression but also at the moment of tumor initiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 2×
“…Kras signals through multiple effector pathways that can impact tumorigenesis (Cully and Downward, 2008; Drosten et al., 2010; Drosten et al., 2014; Malumbres and Barbacid, 2003), a subset of which are required for efficient Kras-driven lung adenocarcinoma formation or tumor maintenance (Engelman…”
BackgroundSomatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Sutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.019 · Cited by 534 · cited 1×
“We therefore utilized adenoviral vectors expressing Cre recombinase under a CC10- or SPC- specific promoter to initiate tumors in a cell-type restricted manner (Sutherland et al., 2011; Sutherland et al., 2014).”
MethodSuppression of lung adenocarcinoma progression by Nkx2-1
Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., et al. (2011) · Nature · doi:10.1038/nature09881 · Cited by 467
Self-citationGenetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347 · cited 1×
“However, oncogenic Kras signals through multiple effector pathways that can impact tumorigenesis (Cully and Downward, 2008; Drosten et al., 2010; Drosten et al., 2014; Malumbres and Barbacid, 2003), a subset of which are required for efficient Kras-driven lung adenocarcinoma formation or tumor…”
BackgroundClassification of Proliferative Pulmonary Lesions of the Mouse
Nikitin, A. Y., Alcaraz, A., Anver, M. R., Bronson, R. T., Cardiff, R. D., Dixon, D., Fraire, A. E., Gabrielson, E. W., Gunning, W. T., Haines, D. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3376 · Cited by 334 · cited 3×
“Using a previously defined tumor grading scheme, we observed that the histological spectrum of tumors was significantly more advanced after PLX4720 treatment compared to control (Figure 1d) (Jackson et al., 2005; Nikitin et al., 2004).”
BackgroundMethodBlasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302 · cited 1×
“Genetic deletion or pharmacological inhibition of the MAPK pathway limits tumor growth in Kras-driven models of lung adenocarcinoma (Blasco et al., 2011; Engelman et al., 2008; Trejo et al., 2012), and a Phase II study of the Mek1/2 inhibitor selumetinib observed a prolongation of progression-free…”
BackgroundMolina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157 · cited 1×
“…and higher levels of phosphorylation specifically for Mek1/2 (pMek) and Erk1/2 (pErk), but not alternative key pathways important in Krasmediated lung tumor initiation or maintenance (Figure 1e, Figures S1 and S2) (Castellano et al., 2013; Green et al., 2015; Molina-Arcas et al., 2013).”
BackgroundSafran, M., Kim, W. Y., Kung, A. L., Horner, J. W., Depinho, R. A., & Kaelin, W. G. (2003) · Molecular Imaging · doi:10.1162/153535003322750637 · Cited by 134
Cited by
A model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182
The ERBB network facilitates KRAS-driven lung tumorigenesis
Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2565 · Cited by 111
Multifaceted role for p53 in pancreatic cancer suppression
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211937120 · Cited by 55
Metadata
- Authors
- Cicchini, M., Buza, E. L., Sagal, K. M., Gudiel, A. A., Durham, A. C., & Feldser, D. M.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 18
- Issue
- 8
- Pages
- 1958-1969
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2590140826
- Cited by
- 35
- References
- 12
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression. https://app.cochat.ai/papers/10.1016/j.celrep.2017.01.069
- The paper
- Cicchini, M., Buza, E. L., Sagal, K. M., Gudiel, A. A., Durham, A. C., & Feldser, D. M. (2017). Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression. Cell Reports. https://doi.org/10.1016/j.celrep.2017.01.069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.